News
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
The inclusion of productivity value in the appraisal of health technologies is a subject of ongoing debate. In this blog, we discuss the potential impact of…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
Berdud, Drummond and Towse (2020) propose a method for establishing a reasonable price for an orphan drug. Assuming prices for drugs are set according to incremental…
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
4 August 2020
In a recently published OHE Consulting Report, we report the long-term return on investment (ROI) per £1 spent on various vaccination programmes from the perspective of…
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
OHE publishes a report quantifying the level of patient access associated with NICE ‘optimised’ recommendations.
The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?
25 June 2020
This year’s OHE lecture addresses the question: how should the world pay for a COVID-19 vaccine? Adrian Towse, Emeritus Director of OHE and Senior Research Fellow…
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
The American Society of Health Economists (ASHEcon) announced Patricia Danzon as recipient of the 2020 Victor R. Fuchs Award. This is given to an economist making…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
OHE authors develop a supply and demand model of pharmaceutical markets to analyse the social welfare distribution between consumers (payers) and developers (industry) to set an…
OHE Awarded Independent Research Organisation (IRO) Status by UKRI
20 May 2020
OHE has been awarded the status of Independent Research Organisation (IRO) by Research Councils UK. This blog comments on the significance of this achievement.
Indication-Based Pricing: Are We All Onboard?
12 May 2020
A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase…